Immune landscape of distinct subtypes in urothelial carcinoma based on immune gene profile

Immune checkpoint blockade (ICB) has become a promising therapy for multiple cancers. However, only a small proportion of patients display a limited antitumor response. The present study aimed to classify distinct immune subtypes and investigate the tumor microenvironment (TME) of urothelial carcino...

Full description

Bibliographic Details
Main Author:	Mou Peng
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-08-01
Series:	Frontiers in Immunology
Subjects:	urothelial carcinoma immune subtypes tumor microenvironment immunotherapy biomarker
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.970885/full

Similar Items

A novel cuproptosis pattern and tumor immune microenvironment characterization in urothelial carcinoma of the bladder
by: Huan Feng, et al.
Published: (2023-08-01)

Mass cytometry reveals immune atlas of urothelial carcinoma
by: Qing Zhang, et al.
Published: (2022-06-01)

Clinical value of anoikis-related genes and molecular subtypes identification in bladder urothelial carcinoma and in vitro validation
by: Ying Dong, et al.
Published: (2023-05-01)

The mutational pattern of homologous recombination repair genes in urothelial carcinoma and its correlation with immunotherapeutic response
by: Junru Chen, et al.
Published: (2023-12-01)

A novel immune classification reveals distinct immune escape mechanism and genomic alterations: implications for immunotherapy in hepatocellular carcinoma
by: Zaoqu Liu, et al.
Published: (2021-01-01)

Immune Microenvironment of Muscular-Invasive Urothelial Carcinoma: The Link to Tumor Immune Cycle and Prognosis
by: Oleksandr Stakhovskyi, et al.
Published: (2022-05-01)

Treatment Strategies and Metabolic Pathway Regulation in Urothelial Cell Carcinoma: A Comprehensive Review
by: Huang-Yu Yang, et al.
Published: (2020-11-01)

Identification of tryptophan metabolism- and immune-related genes signature and prediction of immune infiltration landscape in bladder urothelial carcinoma
by: Guanwen Zhou, et al.
Published: (2023-10-01)

Identification of subtypes correlated with tumor immunity and immunotherapy in cutaneous melanoma
by: Qian Liu, et al.
Published: (2021-01-01)

Immune Subtypes Characterization Identifies Clinical Prognosis, Tumor Microenvironment Infiltration, and Immune Response in Ovarian Cancer
by: Weihong Lu, et al.
Published: (2022-03-01)

Molecular Evolutionary Landscape of the Immune Microenvironment of Head and Neck Cancer
by: Baoyi Shao, et al.
Published: (2023-07-01)

Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients
by: Robert S. Seitz, et al.
Published: (2022-08-01)

Identification of Immune-Related Subtypes and Characterization of Tumor Microenvironment Infiltration in Bladder Cancer
by: Mengjia Huang, et al.
Published: (2021-08-01)

Characterization of the Immune Cell Infiltration Profile in Pancreatic Carcinoma to Aid in Immunotherapy
by: De Luo, et al.
Published: (2021-05-01)

Activation of the chemokine receptor 3 pathway leads to a better response to immune checkpoint inhibitors in patients with metastatic urothelial carcinoma
by: Wenqin Feng, et al.
Published: (2022-05-01)

A Prognostic Model for Predicting Tumor Mutation Burden and Tumor-Infiltrating Immune Cells in Bladder Urothelial Carcinoma
by: Chengbang Wang, et al.
Published: (2022-02-01)

Identification of tumor antigens and immune landscapes for bladder urothelial carcinoma mRNA vaccine
by: Zhuolun Sun, et al.
Published: (2023-01-01)

Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current Evidence
by: Sara Elena Rebuzzi, et al.
Published: (2021-11-01)

Activation of the DDR Pathway Leads to the Down-Regulation of the TGFβ Pathway and a Better Response to ICIs in Patients With Metastatic Urothelial Carcinoma
by: Chaozheng Zhou, et al.
Published: (2021-06-01)

Comprehensive Analyses of Immune Subtypes of Stomach Adenocarcinoma for mRNA Vaccination
by: Weiqiang You, et al.
Published: (2022-07-01)

Multi-Omics Analysis of Novel Signature for Immunotherapy Response and Tumor Microenvironment Regulation Patterns in Urothelial Cancer
by: Guangdi Chu, et al.
Published: (2021-12-01)

Identification of a Novel Tumor Microenvironment Prognostic Signature for Bladder Urothelial Carcinoma
by: Chaojie Xu, et al.
Published: (2022-03-01)

Current Status and Future Perspectives of Immunotherapy for Locally Advanced or Metastatic Urothelial Carcinoma: A Comprehensive Review
by: Tae Jin Kim, et al.
Published: (2020-01-01)

The Identification and Validation of Two Heterogenous Subtypes and a Risk Signature Based on Ferroptosis in Hepatocellular Carcinoma
by: Zaoqu Liu, et al.
Published: (2021-03-01)

Preoperative systemic immune-inflammation index as a prognostic indicator for patients with urothelial carcinoma
by: Jianxiong Zheng, et al.
Published: (2023-11-01)

Immune cell infiltration and immunotherapy in hepatocellular carcinoma
by: Yu Jiang, et al.
Published: (2022-05-01)

Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis
by: Alessandro Rizzo, et al.
Published: (2022-02-01)

Precision Medicine to Treat Urothelial Carcinoma—The Way Forward
by: Carvy Floyd Luceno, et al.
Published: (2023-06-01)

PLAUR as a Potential Biomarker Associated with Immune Infiltration in Bladder Urothelial Carcinoma
by: Liu M, et al.
Published: (2021-09-01)

The Immune Subtypes and Landscape of Advanced-Stage Ovarian Cancer
by: Minjie Zhang, et al.
Published: (2022-09-01)

Identification and validation of molecular subtypes’ characteristics in bladder urothelial carcinoma based on autophagy-dependent ferroptosis
by: Shiwei Liu, et al.
Published: (2023-11-01)

Tumor antigens and immune subtypes of glioblastoma: the fundamentals of mRNA vaccine and individualized immunotherapy development
by: Changwu Wu, et al.
Published: (2022-07-01)

Efficacy of Immune Checkpoint Inhibitors in Upper Tract Urothelial Carcinomas: Current Knowledge and Future Directions
by: Jonathan Thouvenin, et al.
Published: (2021-08-01)

Cost-effectiveness of immune checkpoint inhibitors in treating metastatic urothelial cancer
by: Li-Yu Yang, et al.
Published: (2024-03-01)

Metabolic and Molecular Basis of Sarcopenia: Implications in the Management of Urothelial Carcinoma
by: Hiroshi Fukushima, et al.
Published: (2019-02-01)

Molecular subtype classification of urothelial carcinoma in Lynch syndrome
by: Christina Therkildsen, et al.
Published: (2018-08-01)

The G protein-coupled receptor-related gene signatures for predicting prognosis and immunotherapy response in bladder urothelial carcinoma
by: Wan Zhengqiang, et al.
Published: (2023-08-01)

Molecular subtypes based on cuproptosis-related genes and immune profiles in lung adenocarcinoma
by: Yufei Wang, et al.
Published: (2022-10-01)

Urothelial carcinoma; an overview of histology, molecular subtypes, and clinical implications based on the latest WHO classification
by: Fateme Khalatbari, et al.
Published: (2023-09-01)

Elucidating the Associated Biological Function and Clinical Significance of <i>RHOJ</i> Expression in Urothelial Carcinoma
by: Xin-Jie Lu, et al.
Published: (2023-09-01)